7-Hydroxymitragynine (7-OH) is a minor alkaloid naturally occurring in the leaves of the Mitragyna speciosa plant (kratom). It's structurally similar to the major kratom alkaloid mitragynine, with an added hydroxyl group at the 7-position. Despite being a minor alkaloid by mass, 7-OH has higher receptor activity at the μ-opioid receptor than mitragynine — making it a regulatory focus even though it's a small fraction of typical raw kratom material.
Raw kratom leaf typically measures 0.1-0.4 % 7-OH as a fraction of total alkaloid content. Concentrated extracts can exceed 20 % 7-OH through processing (selective extraction, post-extraction concentration, or spiking with synthesized 7-OH).
The American Kratom Association (AKA), the industry trade association, published its Good Manufacturing Practice (GMP) standard in 2019. The AKA-GMP defines a maximum 7-OH content of 2 % of total alkaloid content for products certified as AKA-GMP compliant.
The 2 % number was chosen because:
Since 2024, FDA enforcement actions on kratom products have specifically called out high-7-OH products as a distinct regulatory category. The reasoning:
DEA has so far stopped short of formal scheduling but has used enforcement targeted at concentrated-7-OH products. The 2 % AKA-GMP cap has become the de facto line that distinguishes enforcement targets from non-targets.
The 2 % threshold is calculated as a ratio:
7-OH % = (7-OH mg/g) / (total alkaloid mg/g) × 100
Where total alkaloid content includes mitragynine, 7-OH, speciogynine, paynantheine, corynantheidine, and other quantified minor alkaloids. The ratio is calculated on a dry-weight basis after moisture correction.
The reference method is LC-MS/MS quantification. Sub-ppm sensitivity is needed to capture trace 7-OH in raw leaf material; the same instrument handles the high-7-OH extracts at percent-level concentrations. Most properly-equipped labs report both 7-OH (mg/g) and the AKA-GMP ratio on the same COA.
Across kratom samples we've tested at Gold Standard Analytics, the distribution of 7-OH content roughly breaks into three populations:
A subtler question: can you tell natural-leaf 7-OH from added synthesized 7-OH? Yes, by looking at the broader alkaloid profile. Natural-leaf kratom has a characteristic ratio of major to minor alkaloids:
The ratios of these alkaloids to each other are characteristic of natural leaf material. Products where 7-OH has been added externally (from synthesized 7-OH or from selective extraction) show profile shifts — high 7-OH but normal levels of the other minor alkaloids. That's a flag for non-natural material.
We report the full 5-plex alkaloid profile on our AKA-GMP Aligned panel ($239) so the profile-vs-spike question can be answered on the same COA.
Several US states have passed kratom-specific legislation since 2018. The state-level approach has varied:
For brands selling kratom across state lines, the AKA-GMP standard provides a consistent compliance target — a COA showing < 2 % 7-OH plus the rest of the AKA-GMP-aligned scope is the document that most state inspectors will accept.
The 2 % 7-OH cap is the regulatory bright line between "whole-leaf kratom" and "concentrated 7-OH product." It comes from the American Kratom Association GMP standard, has been adopted by state KCPA laws, and has been used as a focal point for FDA / DEA enforcement actions since 2024. The cap is testable via LC-MS/MS quantification of 7-OH and total alkaloid content; the AKA-GMP Aligned panel covers all the data points needed to demonstrate compliance.
See our 7-hydroxymitragynine testing panel for the dedicated 7-OH quantification COA, or kratom testing overview for the full AKA-GMP-aligned scope.